Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Development of Stable and Simple Finasteride 333-μg,mL Suspensions that Minimize Occupational Exposure

Author(s):  Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott

Issue:  Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue

Abstract:  Finasteride is not commercially available in a liquid format, which stimulated the development of a stable and simple finasteride suspension formulation. The objectives of this work were to develop and test a finasteride suspension for 1) simplicity to compound, 2) pharmaceutical acceptability, 3) stability, and 4) potential for occupational exposure. The stability of commercial 5-mg finasteride tablets (50 mg/150 mL) was evaluated in water, Oral Mix, and OralMix SF in amber polyethylene terephthalate bottles at 25°C or 4°C. Additional stability studies were carried out using sugar-free Finasteride Powder USP in amber polyethylene terephthalate bottles and tablets in water in polypropylene oral syringes. On study days 0, 1, 3, 7, 14, 28, 38, 49, 63, and 90, the finasteride concentration was determined using a validated stability-indicating liquid chromatographic method. The potential occupational airborne exposure was evaluated by attempting to measure finasteride in 1000 liters of room air following shaking and nebulization. Finasteride suspension/dispersion formulations were prepared in water, Oral Mix, and Oral Mix SF from tablets and pure powder. All formulations retained more than 94.3% of the initial finasteride concentration, with 95% confidence, when stored for up to 90 days at room temperature or 4°C. Simulations of occupational exposure failed to demonstrate the presence of finasteride in room air following attempts to nebulize finasteride mixtures. We conclude that 333-µg/mL suspension/dispersions of finasteride in water or Oral Mix products will have more than 94.3% of the initial finasteride concentration remaining after 90 days, regardless of the formulation, container, or storage temperature. Although we could not detect finasteride in room air, given the analytical limits of the study, we estimate that exposure would unlikely exceed 3.6-µg/1000 liters of room air. Nevertheless, since current regulations are based on “no safe limit,” use of primary engineering controls and personal protective equipment as appropriate is recommended.

Related Keywords: Nathan Ma, RPh, HBSc, PharmD, ACPR, MSc, William Perks, RPh, BSc (Pharm), EMBA, Shirley Law, Dip Pharm Tech, John Iazzetta, PharmD, Scott Walker, MScPhm, finasteride, oral suspension, hazardous drug, occupational exposure, workplace safety, stability, vaporization, aerosolization, dispersion, nebulization

Related Categories: ENVIRONMENTAL , STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, PROFESSIONAL ISSUES

Printer-Friendly Version




Download in electronic PDF format for $45

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Development of Stable and Simple Finasteride 333-μg,mL Suspensions that Minimize Occupational Exposure Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott Nov/Dec 2020 519-527 Buy
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Allen W Chris, Greeson Nicole MH, Mixon William Nov/Dec 2020 451-458 Buy
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration Greeson Nicole MH, Mixon William, Allan W Chris Jul/Aug 2020 270-276 Buy
How to Develop and Maintain a Hazardous Drug List Dillon L Rad May/Jun 2019 182-186 Buy
Stability of Venlafaxine Immediate-Release Suspensions Donnelly Ronald F, Wong Keith, Goddard Rob, Johanson Christel Jan/Feb 2011 81-84 Buy
Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination Allen Loyd V Jr Nov/Dec 2006 446-448 Buy
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists Mixon Bill, Nain John May/Jun 2013 182-190 Buy
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J May/Jun 2018 247-251 Buy
Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon Jul/Aug 2020 322-326 Buy
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel Mar/Apr 2017 160-163 Buy